AOH1996

CHF 150.00
In stock
AG-CR1-3553-M0055 mgCHF 150.00
AG-CR1-3553-M02525 mgCHF 450.00
NEW

Research Use Only (RUO). NOT ALLOWED FOR USE IN HUMANS.

More Information
Product Details
Synonyms NSC789796; N-(2-((2-(3-Methoxyphenoxy)phenyl)amino)-2-oxoethyl)-1-naphthamide
Product Type Chemical
Properties
Formula

C26H22N2O4

MW 426.5
CAS 2089314-64-5
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO (10mg/ml).
Identity Determined by 1H-NMR.
InChi Key HDMONPHKMIZXDH-UHFFFAOYSA-N
Smiles O=C(CNC(C1=C(C=CC=C2)C2=CC=C1)=O)NC3=CC=CC=C3OC4=CC(OC)=CC=C4
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description
  • AOH1996 is an orally available and metabolically stable small molecule PCNA inhibitor, which selectively kills cancer cells, with a median concentration of about 300 nM for 50% growth inhibition. AOH1996 was not significantly toxic to non-malignant cells, even up to 10 µM.
  • AOH1996 enhances the interaction between PCNA and the largest subunit of RNA polymerase II (RNAPII), RPB1, and dissociates PCNA from actively transcribed chromatin regions, while inducing DNA double-stranded breaks in a transcription-dependent manner, leading to the overall degradation of RPB1 and the collapse of replication forks in actively transcribed regions.
  • AOH1996 was created to target a post-translationally modified isoform of PCNA, termed caPCNA, which is preferentially found in cancer cells. PCNA is crucial in the body for DNA repair, but targeting it is difficult because of its role in healthy cells. By selectively targeting caPCNA, it may be possible to kill cancer cells without affecting healthy tissues. In vitro testing demonstrated that AOH1996 inhibited the growth and induced cell cycle arrest (G2/M or S phase arrest) and apoptotic cell death in a wide variety of cancer cell lines, but had no effect on several normal, nonmalignant cell types.
Product References
  1. The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA: L. Gu, et al.; Clin. Cancer Res. 24, 6053 (2018)
  2. Small molecule targeting of transcription-replication conflict for selective chemotherapy: L. Gu, et al.; Cell Chem. Biol. (Epub ahead of print) (2023)
  3. Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination: Y.-C. Wang, et al.; Cell Rep. 42, 112296 (2023) 
  4. Therapeutic Targeting of DNA Replication Stress in Cancer: L. Gu, et al.; Genes 14, 1346 (2023) (Review)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.